Long COVID will take a toll on the nation's healthcare system for the foreseeable future, but we can reduce new cases by treating acute COVID infections with a commonly prescribed, inexpensive medicine.
Yet another potential Covid treatment has fallen by the wayside. This time it's fluvoxamine, an antidepressant, which showed some promise in minimizing serious disease in small trials. But in a large, randomized trial, it flopped completely. The lesson? You need an antiviral drug to treat a viral infection – not a repurposed drug. These have all failed.